PLANTATION, Fla., Dec. 12, 2008 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc.
(GBI) announced today the successful completion of the development work for the
new AREVA drug that will be radio-labeled by the NCI with lead-212 and used to
fight cancer. The completion of this step allows for the cGMP manufacturing of
the conjugated drug that is expected to enter a Phase I clinical trial in 2009.
Stephanie Finnegan, CEO of GBI said "We are proud that AREVA chose us to play a
key role in this new generation of radioimmunotherapy and we look forward to an
auspicious beginning of the clinical trials."
About Goodwin Biotechnology Inc.
GBI is one of the first established biopharmaceutical contract manufacturing
organizations (CMOs), established in 1992. GBI specializes in process
development and cGMP compliant mammalian cell culture manufacturing of
bio-therapeutics for pre-clinical studies through Phase III clinical trials.
GBI's clients include small to midsized biotech companies throughout North
America and Europe, universities, renowned cancer research institutes and
various branches of the U.S. government. GBI offers its clients the depth of
experience of an established US Contract Manufacturing Organization.
www.goodwinbio.com
The Goodwin Biotechnology Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5202
About AREVA Inc.
With manufacturing facilities in 43 countries and a sales network in more than
100, AREVA offers customers reliable technological solutions for CO2-free power
generation and electricity transmission and distribution. We are the world
leader in nuclear power and the only company to cover all industrial activities
in this field. Our 71,000 employees are committed to continuous improvement on
a daily basis, making sustainable development the focal point of the group's
industrial strategy. AREVA's businesses help meet the 21st century's greatest
challenges: making energy available to all, protecting the planet, and acting
responsibly towards future generations. www.areva.com
The AREVA Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5221
This press release may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties.
CONTACT: AREVA Inc.
Patrick Bourdet
(301) 841-1600
patrick.bourdet@areva.com
4800 Hampden Lane, Suite 1100
Bethesda, Maryland 20814
Goodwin Biotechnology Inc.
Stephanie Finnegan, CEO
(954) 327-9606
sfinnegan@goodwinbio.com
1850 NW 69 Avenue
Plantation, Florida 33313
Goodwin Biotechnology Inc. Completes Development of AREVA's New Cancer Treatment
| Source: Goodwin Biotechnology Incorporated